Loading…
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program
The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All ( = 251), ( = 51), ( = 16), and ( = 11) isolates were inhibited by ≤0.12 μg/ml of CD101 a...
Saved in:
| Published in: | Antimicrobial agents and chemotherapy 2017-03, Vol.61 (3) |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-a484t-baff5053dca93bb94081ed92ed6af7002c390f1fdaf026fcdee4921a06f1052c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-a484t-baff5053dca93bb94081ed92ed6af7002c390f1fdaf026fcdee4921a06f1052c3 |
| container_end_page | |
| container_issue | 3 |
| container_start_page | |
| container_title | Antimicrobial agents and chemotherapy |
| container_volume | 61 |
| creator | Pfaller, Michael A Messer, Shawn A Rhomberg, Paul R Castanheira, Mariana |
| description | The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All
(
= 251),
(
= 51),
(
= 16), and
(
= 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or showed wild-type susceptibility to the other echinocandins tested. Five
isolates (
= 100) displayed CD101 MIC values of 1 to 4 μg/ml, had elevated MICs of caspofungin (2 to >8 μg/ml), anidulafungin (2 to 4 μg/ml), and micafungin (2 to 4 μg/ml), and carried mutations on
and
(
= 92) and
(
= 10) displayed higher CD101 MIC values (ranges, 0.5 to 4 μg/ml and 0.12 to 2 μg/ml, respectively), and similar results were observed for the other echinocandins tested. Fluconazole resistance was noted among 11.0% of
isolates, 4.3% of
isolates, and 2.0% of
and
isolates. The activity of CD101 against
(
= 56) was similar to that of micafungin and 2-fold greater than that of caspofungin but less than that of anidulafungin. These isolates had wild-type susceptibility to itraconazole, voriconazole, and posaconazole. The echinocandins had limited activity against
(
= 19). CD101 was as active as the other echinocandins against common fungal organisms recovered from patients with invasive fungal infections. The long half-life profile is very desirable for the prevention and treatment of serious fungal infections, especially in patients who can then be discharged from the hospital to complete antifungal therapy on an outpatient basis. |
| doi_str_mv | 10.1128/aac.02045-16 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5328534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1855790995</sourcerecordid><originalsourceid>FETCH-LOGICAL-a484t-baff5053dca93bb94081ed92ed6af7002c390f1fdaf026fcdee4921a06f1052c3</originalsourceid><addsrcrecordid>eNp1kkFv1DAQhSNERZfCjTPysZVIsZM4jS9IUdiWlVYFscuBkzXr2FlXib21nUj9n_wgHLZU5cDJGs_T9_SeJkneEXxJSFZ9BBCXOMMFTUn5IlkQzKq0pKx8mSwwLsu0qHBxmrz2_g7HmTL8KjnNKkyziuaL5Fctgp50eEBWIUBra7p0_jIdWoq9NlaAabVB581ngskFihPayEka1NjhAA6Cdag2QavRdNCjupMmeLSVPsgWQQfa-BDBN73dxXVj-15GvDWzX2NNkMPBOnAPaGUm8HqS6PpIWnnbQ5AeRfewl2izvN1-_4kyTIrnhpvRTVL3PRgh0TdnOwfDm-REQe_l28f3LPlxvdw2X9L115tVU69TKKoipDtQimKatwJYvtuxAldEtiyTbQnqCuNM5AwrolpQOCuVaKUsWEYAl4rE_kR-lnw6cg_jbpCtiNEd9Pzg9BATcQua_7sxes87O3Gaz-0XEXD-CHD2foyd8UF7Iec00o6ek4rSK4YZo1H64SgVznrvpHqyIZjPh8DruuF_DoGTMsovjnLwQ8bv7OhMbOJ_2vfPYzyB_15J_htTar6j</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1855790995</pqid></control><display><type>article</type><title>Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program</title><source>American Society for Microbiology Journals</source><source>PubMed Central</source><creator>Pfaller, Michael A ; Messer, Shawn A ; Rhomberg, Paul R ; Castanheira, Mariana</creator><creatorcontrib>Pfaller, Michael A ; Messer, Shawn A ; Rhomberg, Paul R ; Castanheira, Mariana</creatorcontrib><description>The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All
(
= 251),
(
= 51),
(
= 16), and
(
= 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or showed wild-type susceptibility to the other echinocandins tested. Five
isolates (
= 100) displayed CD101 MIC values of 1 to 4 μg/ml, had elevated MICs of caspofungin (2 to >8 μg/ml), anidulafungin (2 to 4 μg/ml), and micafungin (2 to 4 μg/ml), and carried mutations on
and
(
= 92) and
(
= 10) displayed higher CD101 MIC values (ranges, 0.5 to 4 μg/ml and 0.12 to 2 μg/ml, respectively), and similar results were observed for the other echinocandins tested. Fluconazole resistance was noted among 11.0% of
isolates, 4.3% of
isolates, and 2.0% of
and
isolates. The activity of CD101 against
(
= 56) was similar to that of micafungin and 2-fold greater than that of caspofungin but less than that of anidulafungin. These isolates had wild-type susceptibility to itraconazole, voriconazole, and posaconazole. The echinocandins had limited activity against
(
= 19). CD101 was as active as the other echinocandins against common fungal organisms recovered from patients with invasive fungal infections. The long half-life profile is very desirable for the prevention and treatment of serious fungal infections, especially in patients who can then be discharged from the hospital to complete antifungal therapy on an outpatient basis.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/aac.02045-16</identifier><identifier>PMID: 28052853</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Antifungal Agents ; Antifungal Agents - pharmacokinetics ; Antifungal Agents - pharmacology ; Asia - epidemiology ; Aspergillosis - drug therapy ; Aspergillosis - epidemiology ; Aspergillosis - microbiology ; Aspergillus fumigatus ; Aspergillus fumigatus - drug effects ; Aspergillus fumigatus - growth & development ; Candida ; Candida - drug effects ; Candida - growth & development ; Candidiasis, Invasive - drug therapy ; Candidiasis, Invasive - epidemiology ; Candidiasis, Invasive - microbiology ; Cryptococcosis - drug therapy ; Cryptococcosis - epidemiology ; Cryptococcosis - microbiology ; Cryptococcus neoformans ; Cryptococcus neoformans - drug effects ; Cryptococcus neoformans - growth & development ; Drug Resistance, Fungal ; Echinocandins ; Echinocandins - pharmacokinetics ; Echinocandins - pharmacology ; Epidemiological Monitoring ; Epidemiology and Surveillance ; Europe - epidemiology ; Fluconazole - pharmacokinetics ; Fluconazole - pharmacology ; Half-Life ; Humans ; Itraconazole - pharmacokinetics ; Itraconazole - pharmacology ; Latin America - epidemiology ; Lipopeptides - pharmacokinetics ; Lipopeptides - pharmacology ; Microbial Sensitivity Tests ; North America - epidemiology ; Triazoles - pharmacokinetics ; Triazoles - pharmacology ; Voriconazole - pharmacokinetics ; Voriconazole - pharmacology</subject><ispartof>Antimicrobial agents and chemotherapy, 2017-03, Vol.61 (3)</ispartof><rights>Copyright © 2017 Pfaller et al.</rights><rights>Copyright © 2017 Pfaller et al. 2017 Pfaller et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a484t-baff5053dca93bb94081ed92ed6af7002c390f1fdaf026fcdee4921a06f1052c3</citedby><cites>FETCH-LOGICAL-a484t-baff5053dca93bb94081ed92ed6af7002c390f1fdaf026fcdee4921a06f1052c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/AAC.02045-16$$EPDF$$P50$$Gasm2$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/AAC.02045-16$$EHTML$$P50$$Gasm2$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,3207,27957,27958,52786,52787,52788,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28052853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pfaller, Michael A</creatorcontrib><creatorcontrib>Messer, Shawn A</creatorcontrib><creatorcontrib>Rhomberg, Paul R</creatorcontrib><creatorcontrib>Castanheira, Mariana</creatorcontrib><title>Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All
(
= 251),
(
= 51),
(
= 16), and
(
= 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or showed wild-type susceptibility to the other echinocandins tested. Five
isolates (
= 100) displayed CD101 MIC values of 1 to 4 μg/ml, had elevated MICs of caspofungin (2 to >8 μg/ml), anidulafungin (2 to 4 μg/ml), and micafungin (2 to 4 μg/ml), and carried mutations on
and
(
= 92) and
(
= 10) displayed higher CD101 MIC values (ranges, 0.5 to 4 μg/ml and 0.12 to 2 μg/ml, respectively), and similar results were observed for the other echinocandins tested. Fluconazole resistance was noted among 11.0% of
isolates, 4.3% of
isolates, and 2.0% of
and
isolates. The activity of CD101 against
(
= 56) was similar to that of micafungin and 2-fold greater than that of caspofungin but less than that of anidulafungin. These isolates had wild-type susceptibility to itraconazole, voriconazole, and posaconazole. The echinocandins had limited activity against
(
= 19). CD101 was as active as the other echinocandins against common fungal organisms recovered from patients with invasive fungal infections. The long half-life profile is very desirable for the prevention and treatment of serious fungal infections, especially in patients who can then be discharged from the hospital to complete antifungal therapy on an outpatient basis.</description><subject>Antifungal Agents</subject><subject>Antifungal Agents - pharmacokinetics</subject><subject>Antifungal Agents - pharmacology</subject><subject>Asia - epidemiology</subject><subject>Aspergillosis - drug therapy</subject><subject>Aspergillosis - epidemiology</subject><subject>Aspergillosis - microbiology</subject><subject>Aspergillus fumigatus</subject><subject>Aspergillus fumigatus - drug effects</subject><subject>Aspergillus fumigatus - growth & development</subject><subject>Candida</subject><subject>Candida - drug effects</subject><subject>Candida - growth & development</subject><subject>Candidiasis, Invasive - drug therapy</subject><subject>Candidiasis, Invasive - epidemiology</subject><subject>Candidiasis, Invasive - microbiology</subject><subject>Cryptococcosis - drug therapy</subject><subject>Cryptococcosis - epidemiology</subject><subject>Cryptococcosis - microbiology</subject><subject>Cryptococcus neoformans</subject><subject>Cryptococcus neoformans - drug effects</subject><subject>Cryptococcus neoformans - growth & development</subject><subject>Drug Resistance, Fungal</subject><subject>Echinocandins</subject><subject>Echinocandins - pharmacokinetics</subject><subject>Echinocandins - pharmacology</subject><subject>Epidemiological Monitoring</subject><subject>Epidemiology and Surveillance</subject><subject>Europe - epidemiology</subject><subject>Fluconazole - pharmacokinetics</subject><subject>Fluconazole - pharmacology</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Itraconazole - pharmacokinetics</subject><subject>Itraconazole - pharmacology</subject><subject>Latin America - epidemiology</subject><subject>Lipopeptides - pharmacokinetics</subject><subject>Lipopeptides - pharmacology</subject><subject>Microbial Sensitivity Tests</subject><subject>North America - epidemiology</subject><subject>Triazoles - pharmacokinetics</subject><subject>Triazoles - pharmacology</subject><subject>Voriconazole - pharmacokinetics</subject><subject>Voriconazole - pharmacology</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kkFv1DAQhSNERZfCjTPysZVIsZM4jS9IUdiWlVYFscuBkzXr2FlXib21nUj9n_wgHLZU5cDJGs_T9_SeJkneEXxJSFZ9BBCXOMMFTUn5IlkQzKq0pKx8mSwwLsu0qHBxmrz2_g7HmTL8KjnNKkyziuaL5Fctgp50eEBWIUBra7p0_jIdWoq9NlaAabVB581ngskFihPayEka1NjhAA6Cdag2QavRdNCjupMmeLSVPsgWQQfa-BDBN73dxXVj-15GvDWzX2NNkMPBOnAPaGUm8HqS6PpIWnnbQ5AeRfewl2izvN1-_4kyTIrnhpvRTVL3PRgh0TdnOwfDm-REQe_l28f3LPlxvdw2X9L115tVU69TKKoipDtQimKatwJYvtuxAldEtiyTbQnqCuNM5AwrolpQOCuVaKUsWEYAl4rE_kR-lnw6cg_jbpCtiNEd9Pzg9BATcQua_7sxes87O3Gaz-0XEXD-CHD2foyd8UF7Iec00o6ek4rSK4YZo1H64SgVznrvpHqyIZjPh8DruuF_DoGTMsovjnLwQ8bv7OhMbOJ_2vfPYzyB_15J_htTar6j</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Pfaller, Michael A</creator><creator>Messer, Shawn A</creator><creator>Rhomberg, Paul R</creator><creator>Castanheira, Mariana</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170301</creationdate><title>Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program</title><author>Pfaller, Michael A ; Messer, Shawn A ; Rhomberg, Paul R ; Castanheira, Mariana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a484t-baff5053dca93bb94081ed92ed6af7002c390f1fdaf026fcdee4921a06f1052c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antifungal Agents</topic><topic>Antifungal Agents - pharmacokinetics</topic><topic>Antifungal Agents - pharmacology</topic><topic>Asia - epidemiology</topic><topic>Aspergillosis - drug therapy</topic><topic>Aspergillosis - epidemiology</topic><topic>Aspergillosis - microbiology</topic><topic>Aspergillus fumigatus</topic><topic>Aspergillus fumigatus - drug effects</topic><topic>Aspergillus fumigatus - growth & development</topic><topic>Candida</topic><topic>Candida - drug effects</topic><topic>Candida - growth & development</topic><topic>Candidiasis, Invasive - drug therapy</topic><topic>Candidiasis, Invasive - epidemiology</topic><topic>Candidiasis, Invasive - microbiology</topic><topic>Cryptococcosis - drug therapy</topic><topic>Cryptococcosis - epidemiology</topic><topic>Cryptococcosis - microbiology</topic><topic>Cryptococcus neoformans</topic><topic>Cryptococcus neoformans - drug effects</topic><topic>Cryptococcus neoformans - growth & development</topic><topic>Drug Resistance, Fungal</topic><topic>Echinocandins</topic><topic>Echinocandins - pharmacokinetics</topic><topic>Echinocandins - pharmacology</topic><topic>Epidemiological Monitoring</topic><topic>Epidemiology and Surveillance</topic><topic>Europe - epidemiology</topic><topic>Fluconazole - pharmacokinetics</topic><topic>Fluconazole - pharmacology</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Itraconazole - pharmacokinetics</topic><topic>Itraconazole - pharmacology</topic><topic>Latin America - epidemiology</topic><topic>Lipopeptides - pharmacokinetics</topic><topic>Lipopeptides - pharmacology</topic><topic>Microbial Sensitivity Tests</topic><topic>North America - epidemiology</topic><topic>Triazoles - pharmacokinetics</topic><topic>Triazoles - pharmacology</topic><topic>Voriconazole - pharmacokinetics</topic><topic>Voriconazole - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pfaller, Michael A</creatorcontrib><creatorcontrib>Messer, Shawn A</creatorcontrib><creatorcontrib>Rhomberg, Paul R</creatorcontrib><creatorcontrib>Castanheira, Mariana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pfaller, Michael A</au><au>Messer, Shawn A</au><au>Rhomberg, Paul R</au><au>Castanheira, Mariana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>61</volume><issue>3</issue><issn>0066-4804</issn><eissn>1098-6596</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>Citation Pfaller MA, Messer SA, Rhomberg PR, Castanheira M. 2017. Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program. Antimicrob Agents Chemother 61:e02045-16. https://doi.org/10.1128/AAC.02045-16.</notes><abstract>The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All
(
= 251),
(
= 51),
(
= 16), and
(
= 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or showed wild-type susceptibility to the other echinocandins tested. Five
isolates (
= 100) displayed CD101 MIC values of 1 to 4 μg/ml, had elevated MICs of caspofungin (2 to >8 μg/ml), anidulafungin (2 to 4 μg/ml), and micafungin (2 to 4 μg/ml), and carried mutations on
and
(
= 92) and
(
= 10) displayed higher CD101 MIC values (ranges, 0.5 to 4 μg/ml and 0.12 to 2 μg/ml, respectively), and similar results were observed for the other echinocandins tested. Fluconazole resistance was noted among 11.0% of
isolates, 4.3% of
isolates, and 2.0% of
and
isolates. The activity of CD101 against
(
= 56) was similar to that of micafungin and 2-fold greater than that of caspofungin but less than that of anidulafungin. These isolates had wild-type susceptibility to itraconazole, voriconazole, and posaconazole. The echinocandins had limited activity against
(
= 19). CD101 was as active as the other echinocandins against common fungal organisms recovered from patients with invasive fungal infections. The long half-life profile is very desirable for the prevention and treatment of serious fungal infections, especially in patients who can then be discharged from the hospital to complete antifungal therapy on an outpatient basis.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>28052853</pmid><doi>10.1128/aac.02045-16</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial agents and chemotherapy, 2017-03, Vol.61 (3) |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5328534 |
| source | American Society for Microbiology Journals; PubMed Central |
| subjects | Antifungal Agents Antifungal Agents - pharmacokinetics Antifungal Agents - pharmacology Asia - epidemiology Aspergillosis - drug therapy Aspergillosis - epidemiology Aspergillosis - microbiology Aspergillus fumigatus Aspergillus fumigatus - drug effects Aspergillus fumigatus - growth & development Candida Candida - drug effects Candida - growth & development Candidiasis, Invasive - drug therapy Candidiasis, Invasive - epidemiology Candidiasis, Invasive - microbiology Cryptococcosis - drug therapy Cryptococcosis - epidemiology Cryptococcosis - microbiology Cryptococcus neoformans Cryptococcus neoformans - drug effects Cryptococcus neoformans - growth & development Drug Resistance, Fungal Echinocandins Echinocandins - pharmacokinetics Echinocandins - pharmacology Epidemiological Monitoring Epidemiology and Surveillance Europe - epidemiology Fluconazole - pharmacokinetics Fluconazole - pharmacology Half-Life Humans Itraconazole - pharmacokinetics Itraconazole - pharmacology Latin America - epidemiology Lipopeptides - pharmacokinetics Lipopeptides - pharmacology Microbial Sensitivity Tests North America - epidemiology Triazoles - pharmacokinetics Triazoles - pharmacology Voriconazole - pharmacokinetics Voriconazole - pharmacology |
| title | Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T13%3A13%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20a%20Long-Acting%20Echinocandin%20(CD101)%20and%20Seven%20Comparator%20Antifungal%20Agents%20Tested%20against%20a%20Global%20Collection%20of%20Contemporary%20Invasive%20Fungal%20Isolates%20in%20the%20SENTRY%202014%20Antifungal%20Surveillance%20Program&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Pfaller,%20Michael%20A&rft.date=2017-03-01&rft.volume=61&rft.issue=3&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/aac.02045-16&rft_dat=%3Cproquest_pubme%3E1855790995%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a484t-baff5053dca93bb94081ed92ed6af7002c390f1fdaf026fcdee4921a06f1052c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1855790995&rft_id=info:pmid/28052853&rfr_iscdi=true |